睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海市第一人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海市第一人民医院Shanghai General Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06686108,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 14 岁 至 55 岁;性别:不限

    登记记录的入选字段

  2. 4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.

    排除标准第 4 条

  3. 3.ECOG score is 0-2 points.

    入选标准第 3 条

  4. 4.Blood routine: ANC ≥ 1.0 × 109/L, PLT ≥ 50 × 109/L.

    入选标准第 4 条

    b. Initial diagnosis of WBC ≥ 100 × 109/L.

    入选标准第 7 条

    9.Blood routine: ANC<1.0 × 109/L or PLT<50 × 109/L.

    排除标准第 9 条

  5. h. Residual lesions before transplantation: Flow cytometry analysis showed that the proportion of abnormal lymphoid cells in the bone marrow was greater than 0.01%; Positive detection of minimal residual lesions in molecular biology; PET-CT scan shows that residual lesions are still active.

    入选标准第 13 条

  6. 12.Pregnant or lactating women.

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06686108,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1.14-55 years old, male,or female.
  2. 2.Patients with allo-HSCT due to T-LBL/ALL, the donor type is not limited.
  3. 3.ECOG score is 0-2 points.
  4. 4.Blood routine: ANC ≥ 1.0 × 109/L, PLT ≥ 50 × 109/L.
  5. 5.One of the following high-risk factors:
  6. a. Age of initial diagnosis ≥ 35 years old.
  7. b. Initial diagnosis of WBC ≥ 100 × 109/L.
  8. c. Initial diagnosis of LDH exceeding the upper limit of normal values.
  9. d. Initial diagnosis of bone marrow involvement (blast cells ≥ 5%).
  10. e. Initial diagnosis of a bulky in the mediastinum (longest diameter ≥ 10cm).
  11. f. ETP immunophenotype.
  12. g. During the induction chemotherapy process, 2 courses did not achieve partial remission and/or 4 courses did not achieve complete remission.
  13. h. Residual lesions before transplantation: Flow cytometry analysis showed that the proportion of abnormal lymphoid cells in the bone marrow was greater than 0.01%; Positive detection of minimal residual lesions in molecular biology; PET-CT scan shows that residual lesions are still active.
  14. i. Based on the ELN recommendation based on adult T-ALL: gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations; t (8; 14) (q24; q11)/MYC rearrangement; t (7; 19) (q34; p13)/TCR-LYL1,TCR-MEF2C; del(5q) (q14).
  15. j. High risk subgroups based on NGS definition: PI3K signaling pathway/NRAS, KRAS/TP53/IKZF1/DNTM3A/IDH1, IDH2 gene mutation with or without NOTCH1, FBXW7/PHF6/EP300 gene mutation.

排除标准:Exclusion Criteria:

  1. 1.Central involvement during any course of the disease.
  2. 2.Patients who have not achieved complete remission before transplantation.
  3. 3.Identify those with available targeted drugs.
  4. 4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.
  5. 5.Individuals who are known to be allergic to demethylating drugs or venetoclax.
  6. 6.Individuals with grade 2 or more degrees of active acute GVHD.
  7. 7.Individuals with moderate to severe chronic GVHD.
  8. 8.T-LBL/ALL relapse (flow cytometry abnormal lymphocyte cell proportion>0.01%, WT1 positive, fusion gene positive, or extramedullary recurrence), or transplant rejection, bone marrow donor cell chimerism<95%.
  9. 9.Blood routine: ANC<1.0 × 109/L or PLT<50 × 109/L.
  10. 10.Combined with severe organ dysfunction; The ratio of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) is more than 3 times the normal value or the normal value of direct bilirubin is more than 3 times; The endogenous creatinine clearance rate (Ccr) is less than 50mL/min or 1.5 times the normal value of blood creatinine, regardless of whether hemodialysis treatment is used.
  11. 11.Merge severe active infections.
  12. 12.Pregnant or lactating women.
  13. 13. Accepting other investigational drugs.
  14. 14.According to the researchers' assessment, the patient may have complications that could lead to other dangers.

引自 ClinicalTrials.gov, NCT06686108, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06686108,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06686108